Asset
EZOGABINE
Xenon Pharmaceuticals Inc. Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04912856 | phase3 | terminated | 2021-08-17 | 2023-11-17 | Xenon Pharmaceuticals Inc. | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE |
| NCT04639310 | phase3 | terminated | 2021-03-29 | 2023-05-16 | Xenon Pharmaceuticals Inc. | XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy |
FDA applications (0)
This company has no applications containing this asset.